Document Detail


The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease.
MedLine Citation:
PMID:  22253234     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Pompe disease is a lysosomal storage disorder caused by deficiency in the enzyme acid α-glucosidase (GAA). Pompe disease is characterized by the accumulation of glycogen, predominantly in muscle tissue, leading to progressive muscle weakness, loss of motor, respiratory, and, in the infantile-onset form, cardiac function. Disease progression is highly variable depending on phenotype, but premature death due to respiratory complications occurs in most patients. Beginning in 2006, approved alglucosidase alfa enzyme replacement therapies [recombinant human (rh) GAA] have been available to treat Pompe patients. Treatment of classic infantile-onset patients, who manifest the severest form of the disease, with alglucosidase alfa (Myozyme®) has led to extended survival and an evolving understanding of the pathophysiology and course of the disease. Moreover, such treatment has brought to light the role of the immune response in abrogating the efficacy of rhGAA in classic infantile-onset patients with severe genetic mutations. Thus, optimization of treatment for such patients includes development and utilization of strategies to prevent or eliminate immune responses, including modulating the immune system (prophylactic and therapeutic immune tolerance induction regimens) and engineering the enzyme to be less immunogenic and more effective. Future research is also critical for evaluating and mitigating novel disease-associated pathologies uncovered by prolonged survival of infantile-onset patients including development of novel therapeutics, and for protein design strategies to increase delivery of enzyme replacement therapy to critical target tissues. Such efforts would be greatly bolstered by further development of predictive animal models and biomarkers to facilitate clinical trials and patient management. Published 2012. This article is a U.S. Government work and is in the public domain in the USA.
Authors:
Emanuela Lacaná; Lynne P Yao; Anne R Pariser; Amy S Rosenberg
Related Documents :
21909994 - Microrna-21: a ubiquitously expressed pro-survival factor in cancer and other diseases.
22189514 - Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy.
22147024 - Dermatological diseases of compulsory notification in brazil.
21980214 - Neurosurgical advances in the treatment of moyamoya disease.
18001264 - Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure.
7485084 - Acquired von willebrand's disease: a rare manifestation of postpartum thyroiditis.
Publication Detail:
Type:  Journal Article     Date:  2012-01-17
Journal Detail:
Title:  American journal of medical genetics. Part C, Seminars in medical genetics     Volume:  160C     ISSN:  1552-4876     ISO Abbreviation:  Am J Med Genet C Semin Med Genet     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-01-24     Completed Date:  2012-07-24     Revised Date:  2013-09-16    
Medline Journal Info:
Nlm Unique ID:  101235745     Medline TA:  Am J Med Genet C Semin Med Genet     Country:  United States    
Other Details:
Languages:  eng     Pagination:  30-9     Citation Subset:  IM    
Copyright Information:
Published 2012 Wiley Periodicals, Inc. This article is a U.S. Government work and is in the public domain in the USA.
Affiliation:
Office of Pharmaceutical Science, Office of Biotechnology Products, Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibody Formation / immunology
Child
Child, Preschool
Disease Progression
Enzyme Replacement Therapy / adverse effects
Female
Glycogen Storage Disease Type II / physiopathology*,  therapy*
Humans
Immune Tolerance*
Immunity, Innate
Immunomodulation*
Infant
Male
United States
alpha-Glucosidases / metabolism*,  therapeutic use
Chemical
Reg. No./Substance:
EC 3.2.1.20/alpha-Glucosidases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Combat Experiences, Pre-Deployment Training, and Outcome of Exposure Therapy for Post-Traumatic Stre...
Next Document:  What rhinologists and allergists should know about the medico-legal implications of corticosteroid u...